Change over period: —
NSE · VENUSREM
VENUS REMEDI
-25.3% from the 52-week high · +170.6% above the low
Venus Remedies Ltd. engages in the manufacture and trade of pharmaceutical products. The company is headquartered in Panchkula, Haryana and currently employs 998 full-time employees. The firm is a global injectable manufacturer, possessing a wide product basket catering to therapeutic segments of anti-infective specially in antimicrobial resistance (AMR), oncology, skin and wound care and pain management. The firm operates in the Pharmaceutical Formulation segment. The company manufactures products catering to the critical care and super specialty segments. The firm's product portfolio includes formulations such as injectables, tablets, and topical preparations. The firm offers solutions in the domains of antimicrobial resistance (AMR), oncology, skin & wound care, neurology, anticoagulants, pain management, herbal portfolio and disinfectants. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful and Nervolize. The company has three manufacturing facilities.
The short version. VENUS REMEDI reported revenue of ₹219 crore for Sep 2026, up 13.5% from a year earlier. Net profit was ₹26 crore (up 30.0% year on year). Return on equity was 15.5% in Mar 2026. Promoter holding was 41.76% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
VENUS REMEDI trades 25.3% below its 52-week high and 170.6% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹219 cr.
Sep 2026 net profit of ₹26 cr.
1.3 pts higher than a year earlier.
Revenue compounded at 11.4% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 219 | 179 | 259 | 180 | 193 | 132 | 195 | 177 |
| Net profit | 26 | 23 | 47 | 26 | 20 | 10 | 21 | 20 |
| Net margin % | 11.7 | 12.8 | 18.3 | 14.2 | 10.4 | 7.3 | 10.8 | 11.1 |
| EPS (₹) | 19.19 | 17.18 | 35.53 | 19.14 | 15.06 | 7.18 | 15.71 | 14.66 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 770 | 648 | 601 | 556 | 599 | 548 | 341 | 372 |
| Net profit | 103 | 45 | 28 | 27 | 41 | 62 | -10 | -31 |
| Net margin % | 13.4 | 7.0 | 4.7 | 4.8 | 6.8 | 11.3 | -2.9 | -8.2 |
| EPS (₹) | 76.89 | 33.9 | 21.32 | 19.88 | 30.47 | 50.04 | -8.1 | -24.87 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 15.5% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 15.5 | 8.1 | 5.8 | 5.8 |
| Return on capital % | 19.4 | 12.4 | 8.2 | 7.4 |
| EBITDA margin % | 20.4 | 14.1 | 11.6 | 12.5 |
| Net margin % | 13.1 | 6.8 | 4.7 | 4.7 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 11.4% | 6.6% |
| Profit CAGR | 57.0% | 10.7% |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Up 2.03 pts over 8 quarters.
Up 0.74 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 41.76 | 41.76 | 41.76 | 41.76 | 41.76 | 41.76 | 41.76 | 41.76 | 0.0 |
| FII | 1.11 | 1.34 | 2.24 | 1.86 | 2.26 | 2.8 | 2.92 | 3.14 | +2.03 |
| DII | 0 | 0 | 0.11 | 0.75 | 1.03 | 1.2 | 0.89 | 0.74 | +0.74 |
| Public | 57.13 | 56.9 | 55.89 | 55.63 | 54.96 | 54.24 | 54.43 | 54.36 | -2.77 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.06% of NAV
- Bandhan BSE Healthcare Index Fund0.06% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for VENUS REMEDI are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about VENUS REMEDI
What is the VENUS REMEDI share price?
VENUS REMEDI (VENUSREM) last closed at ₹1,501.60, up 3.2% on the day. Its 52-week range is ₹537.75 to ₹1,947.00.
What is the market cap of VENUS REMEDI?
VENUS REMEDI has a market capitalisation of about ₹1,937 crore. Its price-to-earnings ratio is 15.9.
How are VENUS REMEDI's latest results?
VENUS REMEDI reported revenue of ₹219 crore for Sep 2026, up 13.5% from a year earlier. Net profit was ₹26 crore (up 30.0% year on year). Return on equity was 15.5% in Mar 2026. Promoter holding was 41.76% in Sep 2026, up 0.00 points over 8 quarters.
Who owns VENUS REMEDI?
As of Sep 2026, shareholding was: Promoter 41.76%, FII 3.14%, DII 0.74%, Public 54.36%.
How many mutual funds hold VENUS REMEDI?
2 mutual fund schemes held VENUS REMEDI in October 2026. That compares with 2 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.